Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth To Revisit Launch Plans For Effexor XR Follow-On

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.
Advertisement

Related Content

Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On
Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On
Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs
Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs
Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled
Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled

Topics

Advertisement
UsernamePublicRestriction

Register

PS064766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel